摘要
目的研究血清CEA、CA242、VEGF的检测在肺癌诊断中的临床意义。方法采用ELISA方法测定96例肺癌患者血清CEA、CA242、VEGF的水平。结果CEA、CA242和VEGF的联合检测的阳性率达到71.9%,明显高于各单项标记物的检测阳性率(分别为42.7%、46.9%、40.6%),Ⅲ+Ⅳ期患者CEA、CA242、VEGF阳性率明显高于Ⅰ+Ⅱ期患者(分别为52.2%vs18.5%、53.6%vs29.6%、47.8%vs22.2%,P<0.05),其值大小明显高于Ⅰ+Ⅱ期患者(分别为33.32±55.91vs5.52±4.96ng/ml、45.82±86.27vs14.6±39.78u/ml、293.15±135.75vs47.91±28.64pg/ml,P<0.01)。结论CEA、CA242、VEGF可用于肺癌的诊断、预后判断,联合检测可提高诊断率。
Objective To investigate the clinical value of serum CEA, CA242 and VEGF in patients with lung cancer. Methods Serum levels of CEA, CA242 and VEGF were detected with ELISA in 96 patients suffering from lung cancer. Results The positive rate of CEA, CA242 and VEGF in combinationwas was 71.9%, which was significantly higher than that of single marker（42.7%、46.9%、40.6%, respectively,P〈0.01）. The positive rates of CEA, CA242 and VEGF in stages Ⅲ and Ⅳ patients were remarkably higher than those in stages Ⅰand Ⅱ patients（52.2% vs 18.5%、53.6% vs 29.6%、47.8% vs 22.2%,P〈0.05）. The values of CEA, CA242 and VEGF were also higher （33.32±55.91 vs 5.52±4.96 ng/ml、45.82±86.27 vs 14.6±39.78 u/ml、293.15±135.75 vs 47.91±28.64 pg/ml,P〈0.01） in the former than the latter. Conclusion The results suggest that determination of CEA, CA242 and VEGF are valuable for the diagnosis of lung cancer and evaluation of patient＇s conditions, and diagnostic value can be enhanced by determination of CEA, CA242 and VEGF in combination.
出处
《临床肺科杂志》
2008年第9期1168-1169,共2页
Journal of Clinical Pulmonary Medicine
